The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Open accessAbstract
Purpose: Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported in 2005. One of these reports, the joint analysis of North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab in Treating Women With HER2-Overexpressing Breast Cancer) and the National Surgical Adjuvant Breast and Bowel Project NSABP B-31 (Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2), was updated in 2011. We now report the planned definitive overall survival (OS) results from this joint analysis along with updates on the disease-free survival (DFS) end point. Methods: In all, 4,046 patients with HER2-positive operable breast cancer were enrolled to receive doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in both trials. The required number of events for the definitive statistical analysis for OS (710 events) was reached in September 2012. Updated analyses of overall DFS and related subgroups were also performed. Results: Median time on study was 8.4 years. Adding trastuzumab to chemotherapy led to a 37% relative improvement in OS (hazard ratio [HR], 0.63; 95% CI, 0.54 to 0.73; P < .001) and an increase in 10-year OS rate from 75.2% to 84%. These results were accompanied by an improvement in DFS of 40% (HR, 0.60; 95% CI, 0.53 to 0.68; P < .001) and increase in 10-year DFS rate from 62.2% to 73.7%. All patient subgroups benefited from addition of this targeted anti-HER2 agent. Conclusion: The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early-stage HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cited by
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Fehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
Self-citationPiccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01204 · Cited by 364
Győrffy, B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16257 · Cited by 361
Metadata
- Authors
- Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, N. E., Mamounas, E., Zujewski, J. A., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-11-20
- Volume
- 32
- Issue
- 33
- Pages
- 3744-3752
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1996778928
- Cited by
- 978
- References
- 1
- FWCI
- 34.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. https://app.cochat.ai/papers/10.1200/jco.2014.55.5730
- The paper
- Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, N. E., Mamounas, E., Zujewski, J. A., & Wolmark, N. (2014). Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.55.5730
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
